\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
MENLO PARK, Calif. , May 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eye care generation company whose goal is to create cutting-edge responses to reshape patients’ care and lives, today announced plans to participate in piper Sandler’s upcoming Virtual Symposium on Ophthalmology and Diabetes.
Sight Sciences control is scheduled to participate in a verbal exchange by the fireplace on Monday, May 23, 2022 at 10:00 a. m. page in: https://investors. sightsciences. com/.
About Sight SciencesSight Sciences is an eye care generation company whose goal is to develop and commercialize cutting-edge solutions to reshape care and improve patients’ lives. By employing minimally invasive or non-invasive approaches to address the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective remedy paradigms that improve patient care and supplant replaced traditional approaches. The company’s OMNI® surgical formula is a minimally invasive glaucoma surgery device (MIGS) indicated to decrease intraocular tension in adult patients with number one open-angle glaucoma. (CAPM), the world’s leading cause of irreversible blindness. The company’s TearCare® formula is 510(k) licensed for the application of localized thermotherapy in adult patients with evaporative dry eye due to Meibomian gland disease (MGD), allowing in-office removal of gland obstructions through physicians to treat the number one cause of dry S. M.
For more information, www. sightsciences. com.
OMNI® and TearCare® are registered with Sight Sciences. © 2022 Sight Sciences. All rights reserved.
Media Contact: Shay SmithHealth Commerce707. 971. 9779shay@healthandcommerce. com
Contact 😛 hilip TaylorGilmartin Group415. 937. 5406Investor. Relations@Sightsciences. com